Oculex Pharmaceuticals

Oculex Pharmaceuticals, Inc. was a biopharmaceutical company founded in 1989 that specialized in developing treatments for serious eye diseases. The company's core technology was a proprietary, biodegradable intraocular drug delivery platform known as DDS®, which allowed for the sustained, controlled release of therapeutic compounds directly to the back of the eye. This system was designed to treat chronic conditions that were previously difficult to manage, such as diabetic macular edema, age-related macular degeneration, and inflammation following cataract surgery.

The company's lead investigational product was Posurdex®, a biodegradable implant that delivered the corticosteroid dexamethasone to the retina. This product, later known as Surodex®, showed promising results in clinical trials by significantly reducing inflammation post-cataract surgery compared to standard eye drops. Oculex also engaged in research collaborations, notably with Allergan, to formulate its delivery systems with Allergan's proprietary compounds targeting diseases in the posterior segment of the eye.

In November 2003, Allergan, Inc. acquired Oculex Pharmaceuticals in an all-cash transaction valued at approximately $230 million. The acquisition was primarily driven by the potential of the Posurdex® technology, with Allergan planning to advance it into Phase 3 clinical trials shortly after the purchase. Prior to its acquisition, Oculex was a privately held company and had raised significant venture capital funding from investors including Perseus-Soros BioPharmaceutical Fund, Bay City Capital, and Aisling Capital.

Keywords: ocular drug delivery, biodegradable implant, ophthalmology, eye diseases, Posurdex, dexamethasone, macular edema, sustained release, intraocular, Allergan acquisition, Surodex, posterior segment, biopharmaceutical, specialty pharmaceutical, retinal diseases, drug delivery platform, anti-inflammatory, uveitis, diabetic retinopathy